The drug price of 'Jakabi' which is used in the treatment of myelofibrosis will be lowered about 40%

Published: 2014-06-05 12:03:24

Updated: 2014-06-05 12:03:24

The drug price of 'Jakabi (ingredient ruxolitinib)' which is used in the treatment of a rare disease, myelofibrosis, will be lowered about 40%.

According to industry sources, on May 30, Novartis Korea submitted economic evaluation result of Jakabi with the content of reducing the price about 40% to Health Insurance Review Agency.

Novartis Korea received sales approval from Ministry of Food an...

Fees

- Email service daily and homepage access.

$300 per month.
5 Email holders per each company.
Anual contract base.